MatriSys Bioscience focuses on the $142 Billion worldwide dermatology and skin care market by developing microbiome-derived therapies for the top dermatology and skin care conditions – Acne, Atopic Dermatitis (AD), Rosacea, Psoriasis, and Skin Infections which have a huge impact on 230 million patients’ quality of life.
LifeSci
MatriSys Bioscience
Meet MatriSys Bioscience, Inc.
MatriSys Bio is the leader in Skin Microbiome therapeutics.
We are the first to isolate, characterize, and clinically test beneficial skin bacteria with therapeutic potential for major skin disorders
• Suitable for both traditional pharmaceutical development (topical products) and skin care
• Our IP includes novel anti-infective and immune modulating peptides produced by proprietary natural bacterial strains (UCSD Gallo Laboratory)
• Phase 2 Proof-of-Concept clinical program ready in Atopic Dermatitis.
We are a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion WW dermatology and skin care market. We are developing therapies for the top 5 dermatology & skin care conditions - Atopic Dermatitis, Rosacea, Psoriasis, Acne, and Skin Infections, which have a huge impact on quality of life.
MatriSys Bio's scientific approach is to rebalance the natural skin microbiome by application of microbial therapies - "Good Bugs" that selectively kill skin pathogens - "Bad Bugs".
UCSD Dermatology Professor Richard Gallo is a co-founder, head of our Scientific Advisory Board, and a world leader in the use of microbes as novel medicines.
Why is your company the best option to solve the problem you're solving?
Atopic dermatitis affects up to a third of pediatrics. We believe that our non-steroidal, non-immune suppressing therapeutic will be the leader in this very large market. Our atopic dermatitis candidate is Phase 2 ready. We have reviewed and approved our development plan with FDA.
What nuggets of info make you interesting? Why do people care about what you're doing?
We are the only product in development for atopic dermatitis that isn't steroidal and immune system blocking. We address the cause of atopic dermatitis - staph. Aureus colonization.
What else do you want us to know?
Following our atopic dermatitis play, we are also developing therapies for Acne, Rosacea, Skin Cancer, and Netherton's Syndrome (an orphan indication).
BEHIND THE COMPANY
CEO/Founder: Mark Wilson
What is your company's secret sauce?
We know how to make room-temperature stable biotherapeutics from these skin microbiome discoveries. Product development is in house.
What inspired you to start/run this company?
I have spent 30 years in biopharmaceutical development. I combined the incredible skin microbiome skin science of UCSD's Richard Gallo with an experienced biopharma development team. Our therapeutics are going to revolutionize the field of skin therapeutics.
What's the best entrepreneurial advice you've received?
Take the money... don't worry about the dilution. The pie will get bigger.
What's the worst entrepreneurial advice you've received?
Don't worry about the board's executive sessions...
What sets your company culture apart?
Bold and flexible. We have brand new science (Skin Microbiome) and a completely novel approach for our first candidate MSB-01 (killing colonized staph. Aureus). The rewards are a whole new class of biotherapeutics.
OTHER COMPANIES
